Category: News

Post

T2 Biosystems Announces 2018 Second Quarter Financial and Operational Results Release and Conference Call Date

LEXINGTON, Mass., July 20, 2018 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that it will release its 2018 second quarter financial and operational results after the market closes on Thursday, August 2, 2018. In...

Post

The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078

New WHO INN stem “-fungerp” signifies a novel class of antifungals Novel generic name highlights the unique attributes of SCY-078 and its potential to address significant unmet needs across multiple indications JERSEY CITY, N.J., July 18, 2018 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections,...

Post

Spero Therapeutics Announces Pricing of Securities Offering

CAMBRIDGE, Mass. , July 12, 2018 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, today announced the pricing of an READ FULL TEXT

Post

SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis

Clinically and mycologically effective and well-tolerated oral dose of SCY-078 identified for use in Phase 3 registration program Results confirm strong clinical activity of oral SCY-078 and suggest improved sustained benefit relative to the standard of care, potentially addressing unmet needs in VVC Initiation of Phase 3 registration program in VVC planned for the fourth...

Post

T2 Biosystems Reports Granting of Inducement Awards

LEXINGTON, Mass., July 09, 2018 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on July 2, 2018 it issued inducement awards to three new employees. These awards were made under T2 Biosystems’ Inducement Award...

Post

Spero Therapeutics Announces Proposed Offering of Common Stock

CAMBRIDGE, Mass. , July 09, 2018 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections, today announced READ FULL TEXT

Post

Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994

Clinical data demonstrate SPR994 to be well tolerated at single and multiple ascending doses Data support selection of SPR994 300 mg TID dose for use in a pivotal Phase 3 clinical trial, planned to initiate around year-end 2018 CAMBRIDGE, Mass. , July 09, 2018 (GLOBE NEWSWIRE) — Spero READ FULL TEXT